Lisdexamfetamine half-life
This page now models the short plasma half-life of unconverted lisdexamfetamine rather than silently substituting the much longer d-amphetamine metabolite.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Lisdexamfetamine: evidence and interpretation notes
What the curve is actually following
This page now models the short plasma half-life of unconverted lisdexamfetamine rather than silently substituting the much longer d-amphetamine metabolite. The metabolite remains the key reason pharmacological effects outlast the parent prodrug curve.
A 48 minutes input gives this profile one auditable line for Unconverted lisdexamfetamine in plasma. The line deliberately stops short of claims about clinical effect, measured concentration, or testing results.
Lisdexamfetamine can vary with formulation, route, metabolism, urine pH, and active metabolites. The curve visualizes a selected pharmacokinetic value rather than alertness, cardiovascular effects, sleep disruption, or performance.
What each source contributes
- DailyMed: LISDEXAMFETAMINE DIMESYLATE CAPSULE [CAMBER PHARMACEUTICALS, INC.]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Lisdexamfetamine. This identity record confirms names and compound identity and does not supply a human half-life.
- Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
For Lisdexamfetamine, the numerical model is tied most closely to DailyMed: LISDEXAMFETAMINE DIMESYLATE CAPSULE [CAMBER PHARMACEUTICALS, INC.]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why there is no range on the chart
This profile plots 0.8 hours for Unconverted lisdexamfetamine in plasma without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 48 min as a representative input for Unconverted lisdexamfetamine in plasma. In the simplified model, about 0.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 4 h.
This is a very fast curve. The useful lesson is not "gone instantly," but how quickly a parent-compound model can move from prominent to low remaining percentages. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
stimulant context
Stimulant half-life estimates can shift with urine pH, enzyme activity, formulation, dose, and whether metabolites are measured separately.
- Alertness or subjective stimulation can end before modeled elimination.
- Sleep disruption and downstream effects are not represented by the curve.
- Formulation and route can change peak timing without changing the displayed model.
ComparisonTimeline checkpoints and nearby profiles
Lisdexamfetamine timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 30 min | 64.8% | Meaningful modeled decline, not near-zero |
| 1 h | 42.0% | Meaningful modeled decline, not near-zero |
| 2 h | 17.7% | Long-tail portion of the model |
| 6 h | 0.55% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Lisdexamfetamine within the stimulant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Cocaine (1 h)
- Nicotine (2 h)
- Mephedrone (2.0 h)
- Methylphenidate (3 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 48 min |
|---|---|
| Modeled analyte or phase | Unconverted lisdexamfetamine in plasma |
| Curve type | Normalized, first-order decline |
Selection note: This page now models the short plasma half-life of unconverted lisdexamfetamine rather than silently substituting the much longer d-amphetamine metabolite. The metabolite remains the key reason pharmacological effects outlast the parent prodrug curve.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: LISDEXAMFETAMINE DIMESYLATE CAPSULE [CAMBER PHARMACEUTICALS, INC.].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Lisdexamfetamine.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the stimulant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.